ArticleAmerican journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics2009
SLC6A4 variation and citalopram response.
Article in American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 136 citations in OpenAlex.
- Genetic variation associated with depression in Latin American populations: a systematic review of single-nucleotide variants.Frontiers in psychiatry · 2026Pooled it
- Systems Approach to Identify Common Genes and Pathways Associated with Response to Selective Serotonin Reuptake Inhibitors and Major Depression Risk.International journal of molecular sciences · 2019Pooled it
- SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2014Trial
- Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study.Journal of clinical psychopharmacology · 2014Trial
- Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response.The pharmacogenomics journal · 2012Trial
- CYP2C19 variation and citalopram response.Pharmacogenetics and genomics · 2011Trial
- Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.Clinical pharmacology and therapeutics · 2011Trial
- Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults.Journal of clinical psychopharmacology · 2010Trial
- Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms.International clinical psychopharmacology · 2010Trial
- Pharmacogenetics studies in STAR*D: strengths, limitations, and results.Psychiatric services (Washington, D.C.) · 2009Trial
- The interplay between SLC6A4 and HTR1A genetic variants that may lead to antidepressant failure.The pharmacogenomics journal · 2025Article
- The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy.Genes · 2023Review
- Precision Medicine in Antidepressants Treatment.Handbook of experimental pharmacology · 2023Review
- Pharmacogenetically Guided Escitalopram Treatment for Pediatric Anxiety Disorders: Protocol for a Double-Blind Randomized Trial.Journal of personalized medicine · 2021Article
- Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression.Advances in experimental medicine and biology · 2021Article
- Association between functional polymorphisms in serotonin transporter gene (SLC6A4) and escitalopram treatment response in depressive patients in a South Indian population.European journal of clinical pharmacology · 2020Article
- Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications.Frontiers in pharmacology · 2019Article
- Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse.Depression and anxiety · 2018Article
- Suggested Biomarkers for Major Depressive Disorder.Noro psikiyatri arsivi · 2018Review
- Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks.Journal of affective disorders · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
The influence of genetic variations in SLC6A4 (serotonin transporter gene) on citalopram treatment of depression using the Sequenced Treatment to Relieve Depression (STAR*D) sample was assessed. Of primary interest were three previously studied polymorphisms: 1) the VNTR variation of the second intron, 2) the indel promoter polymorphism (5HTTLPR or SERT), and 3) a single nucleotide polymorphism (SNP) rs25531. Additionally, SLC6A4 was resequenced to identify new SNPs for exploratory analyses. DNA from 1914 subjects in the STAR*D study were genotyped for the intron 2 VNTR region, the indel promoter polymorphism, and rs25531. Associations of these variants with remission of depressive symptoms were evaluated following citalopram treatment. In white non-Hispanic subjects, variations in the intron 2 VNTR (point-wise P = 0.041) and the indel promoter polymorphism (point-wise P = 0.039) were associated with remission following treatment with citalopram. The haplotype composed of the three candidate loci was also associated with remission, with a global p-value of 0.040 and a maximum statistic simulation p-value of 0.0031 for the S-a-12 haplotype, under a dominant model. One SNP identified through re-sequencing the SLC6A4 gene, Intron7-83-TC, showed point-wise evidence of association, which did not remain significant after correction for the number of SNPs evaluated in this exploratory analysis. No associations between these SLC6A4 variations and remission were found in the white Hispanic or black subjects. These findings suggest that multiple variations in the SLC6A4 gene are associated with remission in white non-Hispanic depressed adults treated with citalopram. The mechanism of action of these variants remains to be determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.